Skip to content

Study · Non-randomized trial · n = 31 · 2017

9 results

Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.

Zobel EH, von Scholten BJ, Lindhardt M, Persson F, Hansen TW, Rossing P

Journal of diabetes and its complications30 Sept 2016Cited by 12 (Europe PMC)

PMID27769801 (opens in a new tab)DOI10.1016/j.jdiacomp.2016.09.016 (opens in a new tab)PepBankPUB-27769801
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, HbA1c fell by 6 mmol/mol after 7 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes, HbA1c fell after 7 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c change at 7 weeks
    Study

    n = 31

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    HbA1c reduction
    −6 mmol/mol
    7 weeks

    Source sentences

    Summary
    After 7weeks HbA1c was reduced 6(95% CI: 3;9)mmol/mol
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  2. 02HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, body weight fell by 2.5 kg after 7 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes, body weight fell after 7 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseBody weight change at 7 weeks
    Study

    n = 31

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    Weight reduction
    −2.5 kg
    7 weeks

    Source sentences

    Summary
    weight 2.5(1.8;3.2)kg
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  3. 03HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, systolic blood pressure changed by 4 mmHg after 7 weeks of liraglutide; the 95% CI (-1 to 9) includes zero.

    In plain wordsIn adults with type 2 diabetes, the 4 mmHg change in systolic blood pressure after 7 weeks of liraglutide was not clearly real.

    Peptide
    Liraglutide
    Outcome
    No significant changeSystolic blood pressure change at 7 weeks
    Study

    n = 31

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    Systolic blood pressure reduction
    −4 mmHg
    7 weeks

    Source sentences

    Summary
    SBP 4(-1;9)mmHg
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  4. 04HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, urinary albumin excretion rate fell by 30% after 7 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes, urinary albumin loss fell after 7 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseUrinary albumin excretion rate change at 7 weeks
    Study

    n = 31

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    UAER reduction
    30%
    7 weeks

    Source sentences

    Summary
    UAER 30(12;44)%
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  5. 05HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes, measured GFR fell by 11 ml/min per 1.73 m2 after 7 weeks of liraglutide.

    In plain wordsIn adults with type 2 diabetes, a measure of kidney filtration fell after 7 weeks of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseMeasured GFR change at 7 weeks
    Study

    n = 31

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    mGFR reduction
    −11 ml/min per 1.73m2
    7 weeks

    Source sentences

    Summary
    mGFR 11(7;14)ml/min per 1.73m2
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  6. 06HumanNon-randomized trialOther

    In adults with type 2 diabetes on liraglutide, mGFR high responders had a larger weight reduction than low responders (4.3 versus 1.9 kg).

    In plain wordsIn adults with type 2 diabetes on liraglutide, people whose kidney filtration fell most also lost more weight than the other people.

    Peptide
    Liraglutide
    Outcome
    Not applicablemGFR high responders versus low responders: weight reduction
    Study

    n = 31

    Comparator
    Low responders
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    Weight reduction, mGFR high responders
    4.3 kg
    high responders
    Weight reduction, mGFR low responders
    1.9 kg
    low responders

    Source sentences

    Summary
    mGFR high responders had a significant reduction in weight compared to low responders (4.3 vs. 1.9kg; p=0.002
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  7. 07HumanNon-randomized trialOther

    In adults with type 2 diabetes on liraglutide, SBP high responders tended to have a larger UAER reduction than low responders (47 versus 23%, p=0.14).

    In plain wordsIn adults with type 2 diabetes on liraglutide, people whose blood pressure fell most tended to lose more urinary albumin, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeSBP high responders versus low responders: UAER reduction
    Study

    n = 31

    Comparator
    Low responders
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Measurements

    UAER reduction, SBP high responders
    47%
    high responders
    UAER reduction, SBP low responders
    23%
    low responders

    Source sentences

    Summary
    SBP high responders had a tendency of a higher reduction in UAER compared to low responders (47 vs. 23%, p=0.14).
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  8. 08HumanNon-randomized trialOther

    In adults with type 2 diabetes on liraglutide, no cross-dependency was observed in any of the other renal risk factors (p>=0.16).

    In plain wordsIn adults with type 2 diabetes on liraglutide, a strong response in one risk factor did not predict a strong response in the others.

    Peptide
    Liraglutide
    Outcome
    No significant changeCross-dependency between other renal risk factors
    Study

    n = 31

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 7 weeksAs given in this study (human).

    Source sentences

    Summary
    No cross-dependency was observed in any of the other renal risk factors (p≥0.16).
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.
  9. 09HumanNon-randomized trialEfficacy outcome

    In adults with type 2 diabetes on liraglutide, treatment response did not differ between 7 weeks and 1 year (p>=0.12).

    In plain wordsIn adults with type 2 diabetes on liraglutide, the response after 7 weeks and after 1 year did not differ.

    Peptide
    Liraglutide
    Outcome
    No significant changeTreatment response at 7 weeks versus 1 year
    Study

    n = 23

    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Treatment response did not differ after 7weeks and 1year (p≥0.12).
    1 context sentence
    Summary · context
    Open-label study: 31 type 2 diabetics treated with liraglutide for 7weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.